The Expanding Therapeutic Utility of Botulinum Neurotoxins

• Published in: Toxins Vol. 10; no. 5; p. 208
• Main Authors: Fonfria, Elena, Maignel, Jacquie, Lezmi, Stephane, Martin, Vincent, Splevins, Andrew, Shubber, Saif, Kalinichev, Mikhail, Foster, Keith, Picaut, Philippe, Krupp, Johannes
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.05.2018; MDPI
• Subjects: Animals; Biocompatibility; Biological effects; Biomedical materials; Bladder; Botulinum toxin; Botulinum Toxins - therapeutic use; Chemical compounds; Drug Administration Routes; Drug Compounding; Dystonia; Formulations; Headache; Humans; Migraine; Neurotoxins; Neurotoxins - therapeutic use; Osteoarthritis; Pain; Peripheral Nervous System Agents - therapeutic use; Pharmacology; Proteins; Review; Serogroup; Spasticity; Toxins; Wound healing; formulation; delivery; new indications
• ISSN: 2072-6651; 2072-6651
• DOI: 10.3390/toxins10050208

Botulinum neurotoxin (BoNT) is a major therapeutic agent that is licensed in neurological indications, such as dystonia and spasticity. The BoNT family, which is produced in nature by clostridial bacteria, comprises several pharmacologically distinct proteins with distinct properties. In this review, we present an overview of the current therapeutic landscape and explore the diversity of BoNT proteins as future therapeutics. In recent years, novel indications have emerged in the fields of pain, migraine, overactive bladder, osteoarthritis, and wound healing. The study of biological effects distal to the injection site could provide future opportunities for disease-tailored BoNT therapies. However, there are some challenges in the pharmaceutical development of BoNTs, such as liquid and slow-release BoNT formulations; and, transdermal, transurothelial, and transepithelial delivery. Innovative approaches in the areas of formulation and delivery, together with highly sensitive analytical tools, will be key for the success of next generation BoNT clinical products.